ACM
MBX

Aquatic Capital Management’s MBX Biosciences MBX Stock Holding History

Aquatic Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,155
Closed -$303K – 1822
2026
Q1 		$303K Buy
+10,155
New +$345K 0.01% 895

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Aquatic Capital Management's MBX Position: Q2 2026 in Review

Aquatic Capital Management sold out of MBX Biosciences (MBX) in Q2 2026, closing a stake of 10,155 shares — an estimated $303K sold.

Aquatic Capital Management first reported a position in MBX in Q1 2026 and held it in 1 quarter. The position peaked at $303K in Q1 2026. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Aquatic Capital Management reported no remaining MBX Biosciences position as of Q2 2026 after selling out during the quarter.
  • Aquatic Capital Management sold 10,155 MBX Biosciences shares in Q2 2026, an estimated $303K.
  • Aquatic Capital Management first reported a position in MBX Biosciences in Q1 2026 and held it in 1 quarter.
  • Aquatic Capital Management's MBX Biosciences position peaked at $303K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.